# HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

Study · id `cardio:ct-nct01576341` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01576341](<https://clinicaltrials.gov/study/NCT01576341>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01576341

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 417 participants.

## Technical summary

Registry record NCT01576341. Allocation not applicable; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2014-10 (actual). Results posted on 2017-06-19.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 417 participants (enrolled count; ClinicalTrials.gov record NCT01576341, source copy `cardio:ctgov-nct01576341-2017-06-19`, retrieved 2026-10-26)
- Start date: 2012-04 (registry gives no type) (ClinicalTrials.gov record NCT01576341, source copy `cardio:ctgov-nct01576341-2017-06-19`, retrieved 2026-10-26)
- Primary completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01576341, source copy `cardio:ctgov-nct01576341-2017-06-19`, retrieved 2026-10-26)
- Completion: 2015-06 (actual) (ClinicalTrials.gov record NCT01576341, source copy `cardio:ctgov-nct01576341-2017-06-19`, retrieved 2026-10-26)
- Results first posted: 2017-06-19 (ClinicalTrials.gov record NCT01576341, source copy `cardio:ctgov-nct01576341-2017-06-19`, retrieved 2026-10-26)
- Countries: Germany; Italy; Poland; Romania; Russia; Türkiye; Ukraine (ClinicalTrials.gov record NCT01576341, source copy `cardio:ctgov-nct01576341-2017-06-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01576341-2017-06-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
- Acronym: SENSE
- Condition: Chronic Kidney Disease
- Intervention (Drug): HX575 epoetin alfa (Sandoz)
- Lead sponsor: Sandoz
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 69a753b901d779020fcfba5b1fb6771ff0e3c30f0f4465edee8871e6def4dbc1
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
